Lipidor AB (publ) publishes annual report for 2021

STOCKHOLM, Sweden, 28th April 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the financial year 2021. The report is available on the company’s website and in the attached pdf.

The information was provided for publication by Lipidor’s CEO on 28th April 2022 at 3.30 pm (CEST). 

For more information, please contact

Lipidor AB (Reg. No. 556779-7500)
Ola Holmlund, CEO
Phone: +46 72 50 70 369
Sva?rdva?gen 13
182 33 Danderyd

Certified Advisor

Erik Penser Bank AB
Apelbergsgatan 27, Box 7405
103 91 Stockholm

About Lipidor AB

Lipidor AB ( is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.